Molecular reorganization of endocannabinoid signalling in Alzheimer's disease

Jan Mulder, Misha Zilberter, Susana J. Pasquaré, A. Alpár, Gunnar Schulte, Samira G. Ferreira, Attila Köfalvi, Ana M. Martín-Moreno, Erik Keimpema, Heikki Tanila, Masahiko Watanabe, Ken MacKie, T. Hortobágyi, Maria L. De Ceballos, Tibor Harkany

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors. Cognitive decline in Alzheimer's disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurotransmission in Alzheimer's disease. Comparative protein profiling and quantitative morphometry showed that overall CB1 cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer's disease remain unchanged relative to age-matched controls, and CB1 cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer's (Braak stage VI), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing CB1 cannabinoid receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable Alzheimer's disease (Braak stage III). However, Alzheimer's pathology differentially impacts serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase α/β-hydrolase domain-containing 6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary pathology. Here, monoacylglycerol lipase accumulates in CB1 cannabinoid receptor-positive presynapses. Subcellular fractionation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer's tissues, suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer's disease by demonstrating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with amyloid-β. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer's disease.

Original languageEnglish
Pages (from-to)1041-1060
Number of pages20
JournalBrain
Volume134
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Endocannabinoids
Monoacylglycerol Lipases
Cannabinoid Receptor CB1
Hydrolases
Alzheimer Disease
Amyloid Plaques
Serine
Lipoprotein Lipase
Pyramidal Cells
Microglia
Amyloid
Neurotransmitter Agents
Hippocampus
Pathology
Neurons
Neurofibrillary Tangles
Proteins
2-arachidonylglycerol
Synaptic Transmission
Synapses

Keywords

  • glia
  • human
  • neurodegeneration
  • retrograde signalling
  • synapse

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Mulder, J., Zilberter, M., Pasquaré, S. J., Alpár, A., Schulte, G., Ferreira, S. G., ... Harkany, T. (2011). Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain, 134(4), 1041-1060. https://doi.org/10.1093/brain/awr046

Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. / Mulder, Jan; Zilberter, Misha; Pasquaré, Susana J.; Alpár, A.; Schulte, Gunnar; Ferreira, Samira G.; Köfalvi, Attila; Martín-Moreno, Ana M.; Keimpema, Erik; Tanila, Heikki; Watanabe, Masahiko; MacKie, Ken; Hortobágyi, T.; De Ceballos, Maria L.; Harkany, Tibor.

In: Brain, Vol. 134, No. 4, 04.2011, p. 1041-1060.

Research output: Contribution to journalArticle

Mulder, J, Zilberter, M, Pasquaré, SJ, Alpár, A, Schulte, G, Ferreira, SG, Köfalvi, A, Martín-Moreno, AM, Keimpema, E, Tanila, H, Watanabe, M, MacKie, K, Hortobágyi, T, De Ceballos, ML & Harkany, T 2011, 'Molecular reorganization of endocannabinoid signalling in Alzheimer's disease', Brain, vol. 134, no. 4, pp. 1041-1060. https://doi.org/10.1093/brain/awr046
Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain. 2011 Apr;134(4):1041-1060. https://doi.org/10.1093/brain/awr046
Mulder, Jan ; Zilberter, Misha ; Pasquaré, Susana J. ; Alpár, A. ; Schulte, Gunnar ; Ferreira, Samira G. ; Köfalvi, Attila ; Martín-Moreno, Ana M. ; Keimpema, Erik ; Tanila, Heikki ; Watanabe, Masahiko ; MacKie, Ken ; Hortobágyi, T. ; De Ceballos, Maria L. ; Harkany, Tibor. / Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. In: Brain. 2011 ; Vol. 134, No. 4. pp. 1041-1060.
@article{c12e360b3b1243bfb8f9242254081615,
title = "Molecular reorganization of endocannabinoid signalling in Alzheimer's disease",
abstract = "Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors. Cognitive decline in Alzheimer's disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurotransmission in Alzheimer's disease. Comparative protein profiling and quantitative morphometry showed that overall CB1 cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer's disease remain unchanged relative to age-matched controls, and CB1 cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer's (Braak stage VI), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing CB1 cannabinoid receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable Alzheimer's disease (Braak stage III). However, Alzheimer's pathology differentially impacts serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase α/β-hydrolase domain-containing 6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary pathology. Here, monoacylglycerol lipase accumulates in CB1 cannabinoid receptor-positive presynapses. Subcellular fractionation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer's tissues, suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer's disease by demonstrating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with amyloid-β. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer's disease.",
keywords = "glia, human, neurodegeneration, retrograde signalling, synapse",
author = "Jan Mulder and Misha Zilberter and Pasquar{\'e}, {Susana J.} and A. Alp{\'a}r and Gunnar Schulte and Ferreira, {Samira G.} and Attila K{\"o}falvi and Mart{\'i}n-Moreno, {Ana M.} and Erik Keimpema and Heikki Tanila and Masahiko Watanabe and Ken MacKie and T. Hortob{\'a}gyi and {De Ceballos}, {Maria L.} and Tibor Harkany",
year = "2011",
month = "4",
doi = "10.1093/brain/awr046",
language = "English",
volume = "134",
pages = "1041--1060",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Molecular reorganization of endocannabinoid signalling in Alzheimer's disease

AU - Mulder, Jan

AU - Zilberter, Misha

AU - Pasquaré, Susana J.

AU - Alpár, A.

AU - Schulte, Gunnar

AU - Ferreira, Samira G.

AU - Köfalvi, Attila

AU - Martín-Moreno, Ana M.

AU - Keimpema, Erik

AU - Tanila, Heikki

AU - Watanabe, Masahiko

AU - MacKie, Ken

AU - Hortobágyi, T.

AU - De Ceballos, Maria L.

AU - Harkany, Tibor

PY - 2011/4

Y1 - 2011/4

N2 - Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors. Cognitive decline in Alzheimer's disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurotransmission in Alzheimer's disease. Comparative protein profiling and quantitative morphometry showed that overall CB1 cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer's disease remain unchanged relative to age-matched controls, and CB1 cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer's (Braak stage VI), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing CB1 cannabinoid receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable Alzheimer's disease (Braak stage III). However, Alzheimer's pathology differentially impacts serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase α/β-hydrolase domain-containing 6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary pathology. Here, monoacylglycerol lipase accumulates in CB1 cannabinoid receptor-positive presynapses. Subcellular fractionation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer's tissues, suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer's disease by demonstrating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with amyloid-β. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer's disease.

AB - Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors. Cognitive decline in Alzheimer's disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurotransmission in Alzheimer's disease. Comparative protein profiling and quantitative morphometry showed that overall CB1 cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer's disease remain unchanged relative to age-matched controls, and CB1 cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer's (Braak stage VI), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing CB1 cannabinoid receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable Alzheimer's disease (Braak stage III). However, Alzheimer's pathology differentially impacts serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase α/β-hydrolase domain-containing 6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary pathology. Here, monoacylglycerol lipase accumulates in CB1 cannabinoid receptor-positive presynapses. Subcellular fractionation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer's tissues, suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer's disease by demonstrating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with amyloid-β. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer's disease.

KW - glia

KW - human

KW - neurodegeneration

KW - retrograde signalling

KW - synapse

UR - http://www.scopus.com/inward/record.url?scp=79953672641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953672641&partnerID=8YFLogxK

U2 - 10.1093/brain/awr046

DO - 10.1093/brain/awr046

M3 - Article

C2 - 21459826

AN - SCOPUS:79953672641

VL - 134

SP - 1041

EP - 1060

JO - Brain

JF - Brain

SN - 0006-8950

IS - 4

ER -